Document Detail


Unkei-to for correcting luteal phase defects.
MedLine Citation:
PMID:  14562640     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To assess the clinical efficacy of Unkei-to in women with luteal phase defects. STUDY DESIGN: A study of 103 consecutive subjects with luteal phase defects treated with unkei-to (7.5 g/d) and 94 control subjects was conducted. A venous blood sample was taken, and plasma gonadotropins, 17 beta-estradiol and progesterone levels were measured. Dominant follicle size and endometrial thickness were assessed in the late follicular phase. RESULTS: Unkei-to significantly decreased plasma luteinizing hormone and significantly increased 17 beta-estradiol concentration in the follicular phase and significantly increased progesterone (66.7%) in the midluteal phase (P < .05). Significant development of the dominant follicle (P < .01) and endometrium (P < .001) was also observed in patients treated with unkei-to. We observed significant prolongation of the luteal phase (43%, P < .001) as measured by basal body temperature. There was a 79.6% rate of correction of luteal phase defects in patients treated with unkei-to. Furthermore, the pregnancy rate in patients desiring pregnancy was 49.5% (41/83). CONCLUSION: Administration of unkei-to may normalize the gonadotropin-ovarian endocrine system and/or their interaction in the follicular phase and may improve the endocrine environment in the luteal phase in patients with luteal phase defects.
Authors:
Takahisa Ushiroyama; Atsushi Ikeda; Satoko Higashio; Toshimitsu Hosotani; Hidetoshi Yamashita; Yoshiki Yamashita; Yoshihiko Suzuki; Minoru Ueki
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  The Journal of reproductive medicine     Volume:  48     ISSN:  0024-7758     ISO Abbreviation:  J Reprod Med     Publication Date:  2003 Sep 
Date Detail:
Created Date:  2003-10-17     Completed Date:  2004-01-23     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0173343     Medline TA:  J Reprod Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  729-34     Citation Subset:  IM    
Affiliation:
Department of Obstetrics and Gynecology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka 569-8686, Japan. gyn003@poh.osaka-med.ac.jp
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Body Temperature
Drugs, Chinese Herbal / therapeutic use*
Endometrium / drug effects
Estradiol / blood
Female
Follicle Stimulating Hormone / blood
Follicular Phase
Humans
Luteal Phase* / drug effects
Luteinizing Hormone / blood
Menstruation Disturbances / drug therapy*
Ovarian Follicle / drug effects,  physiology
Ovulation / drug effects
Pregnancy
Progesterone / blood
Time Factors
Chemical
Reg. No./Substance:
0/Drugs, Chinese Herbal; 0/unkei-to; 50-28-2/Estradiol; 57-83-0/Progesterone; 9002-67-9/Luteinizing Hormone; 9002-68-0/Follicle Stimulating Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Obstetric and gynecologic complications in women with Marfan syndrome.
Next Document:  Association of an A allele for interleukin-10 -627 gene promoter polymorphism with higher susceptibi...